Recombinant human insulin-like growth factor-I therapy improves glycemic control and insulin action in the type A syndrome of severe insulin resistance.

Morrow LA, O'Brien MB, Moller DE, Flier JS, Moses AC

The Journal of clinical endocrinology and metabolism1 Jul 1994Cited by 57 (Europe PMC)

PMID8027228DOI10.1210/jcem.79.1.8027228PepBankPUB-08027228

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

01HumanCase report or seriesEfficacy outcome
In subject 1 with type A severe insulin resistance, mean daily blood glucose fell during rhIGF-I treatment.
In plain wordsIn subject 1 with severe insulin resistance, mean daily blood glucose fell during rhIGF-I treatment.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseSubject 1 mean 24-h glucose
Study
n = 1
Outcome group
Glycemic control · Metabolic and weight
Studied dose
100 micrograms/kg twice daily · subcutaneous · 3-4 weeksAs given in this study (human).
Measurements
Mean 24-h blood glucose
8.1 mmol/L
subject 1, before rhIGF-I
Mean 24-h blood glucose
4.2 mmol/L
subject 1, during rhIGF-I
Reported +/- term for Mean 24-h blood glucose
2.7 mmol/L
subject 1, before rhIGF-I; uncertainty type not stated
Reported +/- term for Mean 24-h blood glucose
0.9 mmol/L
subject 1, during rhIGF-I; uncertainty type not stated
Source sentences
Summary
In subject 1, the 24-h mean blood glucose level was 8.1 +/- 2.7 mmol/L before rhIGF-I treatment and fell to 4.2 +/- 0.9 mmol/L during rhIGF-I treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
Two subjects with the type A phenotype of severe insulin resistance without insulin receptor mutations were investigated to assess insulin secretion, insulin action, and carbohydrate tolerance before and after 3-4 weeks of rhIGF-I treatment (100 micrograms/kg, sc, twice daily).
Report a problemFND-0802722801
02HumanCase report or seriesEfficacy outcome
In subject 1 with type A severe insulin resistance, mean daily serum insulin fell during rhIGF-I treatment.
In plain wordsIn subject 1 with severe insulin resistance, mean daily serum insulin fell during rhIGF-I treatment.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseSubject 1 mean 24-h insulin
Study
n = 1
Outcome group
Glycemic control · Metabolic and weight
Studied dose
100 micrograms/kg twice daily · subcutaneous · 3-4 weeksAs given in this study (human).
Measurements
Mean 24-h serum insulin
10,251 pmol/L
subject 1, before rhIGF-I
Mean 24-h serum insulin
1533 pmol/L
subject 1, during rhIGF-I
Reported +/- term for Mean 24-h serum insulin
8849 pmol/L
subject 1, before rhIGF-I; uncertainty type not stated
Reported +/- term for Mean 24-h serum insulin
1198 pmol/L
subject 1, during rhIGF-I; uncertainty type not stated
Source sentences
Summary
The pretreatment 24-h mean serum insulin level was 10,251 +/- 8,849 pmol/L and fell to 1533 +/- 1198 pmol/L.
2 context sentences(design, population, supporting numbers)
Summary · context
In subject 1, the 24-h mean blood glucose level was 8.1 +/- 2.7 mmol/L before rhIGF-I treatment and fell to 4.2 +/- 0.9 mmol/L during rhIGF-I treatment.
Summary · context
Two subjects with the type A phenotype of severe insulin resistance without insulin receptor mutations were investigated to assess insulin secretion, insulin action, and carbohydrate tolerance before and after 3-4 weeks of rhIGF-I treatment (100 micrograms/kg, sc, twice daily).
Report a problemFND-0802722802
03HumanCase report or seriesEfficacy outcome
In subject 1 with type A severe insulin resistance, fasting glucose fell from 4.4 to 3.4 mmol/L during rhIGF-I treatment.
In plain wordsIn subject 1 with severe insulin resistance, fasting glucose fell during rhIGF-I treatment.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseSubject 1 fasting glucose
Study
n = 1
Outcome group
Glycemic control · Metabolic and weight
Studied dose
100 micrograms/kg twice daily · subcutaneous · 3-4 weeksAs given in this study (human).
Measurements
Fasting blood glucose
4.4 mmol/L
subject 1, before rhIGF-I
Fasting blood glucose
3.4 mmol/L
subject 1, during rhIGF-I
Source sentences
Summary
Fasting blood glucose fell from 4.4 to 3.4 mmol/L, and 2-h blood glucose after Sustacal administration fell from 10.3 to 5.3 mmol/L.
1 context sentence(design, population, supporting numbers)
Summary · context
Two subjects with the type A phenotype of severe insulin resistance without insulin receptor mutations were investigated to assess insulin secretion, insulin action, and carbohydrate tolerance before and after 3-4 weeks of rhIGF-I treatment (100 micrograms/kg, sc, twice daily).
Report a problemFND-0802722803
04HumanCase report or seriesEfficacy outcome
In subject 1 with type A severe insulin resistance, post-Sustacal glucose fell from 10.3 to 5.3 mmol/L during rhIGF-I treatment.
In plain wordsIn subject 1 with severe insulin resistance, glucose after Sustacal fell during rhIGF-I treatment.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseSubject 1 post-Sustacal glucose
Study
n = 1
Outcome group
Glycemic control · Metabolic and weight
Studied dose
100 micrograms/kg twice daily · subcutaneous · 3-4 weeksAs given in this study (human).
Measurements
2-h blood glucose after Sustacal
10.3 mmol/L
subject 1, before rhIGF-I
2-h blood glucose after Sustacal
5.3 mmol/L
subject 1, during rhIGF-I
Source sentences
Summary
Fasting blood glucose fell from 4.4 to 3.4 mmol/L, and 2-h blood glucose after Sustacal administration fell from 10.3 to 5.3 mmol/L.
1 context sentence(design, population, supporting numbers)
Summary · context
Two subjects with the type A phenotype of severe insulin resistance without insulin receptor mutations were investigated to assess insulin secretion, insulin action, and carbohydrate tolerance before and after 3-4 weeks of rhIGF-I treatment (100 micrograms/kg, sc, twice daily).
Report a problemFND-0802722804
05HumanCase report or seriesEfficacy outcome
In subject 1 with type A severe insulin resistance, fasting insulin declined from 808 to 246 pmol/L during rhIGF-I treatment.
In plain wordsIn subject 1 with severe insulin resistance, fasting insulin declined during rhIGF-I treatment.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseSubject 1 fasting insulin
Study
n = 1
Outcome group
Glycemic control · Metabolic and weight
Studied dose
100 micrograms/kg twice daily · subcutaneous · 3-4 weeksAs given in this study (human).
Measurements
Fasting serum insulin
808 pmol/L
subject 1, before rhIGF-I
Fasting serum insulin
246 pmol/L
subject 1, during rhIGF-I
Source sentences
Summary
Fasting serum insulin declined from 808 to 246 pmol/L, and the 2-h serum insulin level fell from 5,491 to 3,443 pmol/L.
1 context sentence(design, population, supporting numbers)
Summary · context
Two subjects with the type A phenotype of severe insulin resistance without insulin receptor mutations were investigated to assess insulin secretion, insulin action, and carbohydrate tolerance before and after 3-4 weeks of rhIGF-I treatment (100 micrograms/kg, sc, twice daily).
Report a problemFND-0802722805
06HumanCase report or seriesEfficacy outcome
In subject 1 with type A severe insulin resistance, the 2-h serum insulin level fell during rhIGF-I treatment.
In plain wordsIn subject 1 with severe insulin resistance, the 2-h serum insulin level fell during rhIGF-I treatment.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseSubject 1 post-meal insulin
Study
n = 1
Outcome group
Glycemic control · Metabolic and weight
Studied dose
100 micrograms/kg twice daily · subcutaneous · 3-4 weeksAs given in this study (human).
Measurements
2-h serum insulin
5491 pmol/L
subject 1, before rhIGF-I
2-h serum insulin
3443 pmol/L
subject 1, during rhIGF-I
Source sentences
Summary
Fasting serum insulin declined from 808 to 246 pmol/L, and the 2-h serum insulin level fell from 5,491 to 3,443 pmol/L.
1 context sentence(design, population, supporting numbers)
Summary · context
Two subjects with the type A phenotype of severe insulin resistance without insulin receptor mutations were investigated to assess insulin secretion, insulin action, and carbohydrate tolerance before and after 3-4 weeks of rhIGF-I treatment (100 micrograms/kg, sc, twice daily).
Report a problemFND-0802722806
07HumanCase report or seriesEfficacy outcome
In subject 1 with severe insulin resistance, glucose fell by 20% after insulin before rhIGF-I and by 67% during treatment.
In plain wordsIn subject 1 with severe insulin resistance, glucose fell more after injected insulin during rhIGF-I treatment than before treatment.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseSubject 1 insulin tolerance response
Study
n = 1
Outcome group
Glycemic control · Metabolic and weight
Studied dose
100 micrograms/kg twice daily · subcutaneous · 3-4 weeksAs given in this study (human).
Measurements
Glucose fall after bolus iv insulin
20%
subject 1, before rhIGF-I
Glucose fall after bolus iv insulin
67%
subject 1, during rhIGF-I
Source sentences
Summary
After bolus iv insulin injection (0.15 U/kg), glucose fell by 20% before rhIGF-I treatment and by 67% during rhIGF-I treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
Two subjects with the type A phenotype of severe insulin resistance without insulin receptor mutations were investigated to assess insulin secretion, insulin action, and carbohydrate tolerance before and after 3-4 weeks of rhIGF-I treatment (100 micrograms/kg, sc, twice daily).
Report a problemFND-0802722807
08HumanCase report or seriesEfficacy outcome
In subject 1 with type A severe insulin resistance, steady state plasma glucose fell during rhIGF-I treatment.
In plain wordsIn subject 1 with severe insulin resistance, steady state plasma glucose fell during rhIGF-I treatment.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseSubject 1 steady state plasma glucose
Study
n = 1
Outcome group
Glycemic control · Metabolic and weight
Studied dose
100 micrograms/kg twice daily · subcutaneous · 3-4 weeksAs given in this study (human).
Measurements
Steady state plasma glucose
18.2 mmol/L
subject 1, before rhIGF-I
Steady state plasma glucose
10.8 mmol/L
subject 1, during rhIGF-I
Reported +/- term for Steady state plasma glucose
0.7 mmol/L
subject 1, before rhIGF-I; uncertainty type not stated
Reported +/- term for Steady state plasma glucose
0.1 mmol/L
subject 1, during rhIGF-I; uncertainty type not stated
Source sentences
Summary
The steady state plasma glucose level was 18.2 +/- 0.7 before rhIGF-I and 10.8 +/- 0.1 mmol/L during rhIGF-I.
1 context sentence(design, population, supporting numbers)
Summary · context
Two subjects with the type A phenotype of severe insulin resistance without insulin receptor mutations were investigated to assess insulin secretion, insulin action, and carbohydrate tolerance before and after 3-4 weeks of rhIGF-I treatment (100 micrograms/kg, sc, twice daily).
Report a problemFND-0802722808
09HumanCase report or seriesEfficacy outcome
In subject 2 with type A severe insulin resistance, fasting glucose fell from 12.0 to 7.4 mmol/L during rhIGF-I treatment.
In plain wordsIn subject 2 with severe insulin resistance, fasting glucose fell during rhIGF-I treatment.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseSubject 2 fasting glucose
Study
n = 1
Outcome group
Glycemic control · Metabolic and weight
Studied dose
100 micrograms/kg twice daily · subcutaneous · 3-4 weeksAs given in this study (human).
Measurements
Fasting blood glucose
12 mmol/L
subject 2, before rhIGF-I
Fasting blood glucose
7.4 mmol/L
subject 2, during rhIGF-I
Source sentences
Summary
In subject 2, fasting blood glucose fell from 12.0 to 7.4 mmol/L and 24-h mean blood glucose fell from 12.7 +/- 1.9 to 6.6 +/- 1.3 mmol/L.
1 context sentence(design, population, supporting numbers)
Summary · context
Two subjects with the type A phenotype of severe insulin resistance without insulin receptor mutations were investigated to assess insulin secretion, insulin action, and carbohydrate tolerance before and after 3-4 weeks of rhIGF-I treatment (100 micrograms/kg, sc, twice daily).
Report a problemFND-0802722809
10HumanCase report or seriesEfficacy outcome
In subject 2 with type A severe insulin resistance, mean daily blood glucose fell during rhIGF-I treatment.
In plain wordsIn subject 2 with severe insulin resistance, mean daily blood glucose fell during rhIGF-I treatment.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseSubject 2 mean 24-h glucose
Study
n = 1
Outcome group
Glycemic control · Metabolic and weight
Studied dose
100 micrograms/kg twice daily · subcutaneous · 3-4 weeksAs given in this study (human).
Measurements
24-h mean blood glucose
12.7 mmol/L
subject 2, before rhIGF-I
24-h mean blood glucose
6.6 mmol/L
subject 2, during rhIGF-I
Reported +/- term for 24-h mean blood glucose
1.9 mmol/L
subject 2, before rhIGF-I; uncertainty type not stated
Reported +/- term for 24-h mean blood glucose
1.3 mmol/L
subject 2, during rhIGF-I; uncertainty type not stated
Source sentences
Summary
In subject 2, fasting blood glucose fell from 12.0 to 7.4 mmol/L and 24-h mean blood glucose fell from 12.7 +/- 1.9 to 6.6 +/- 1.3 mmol/L.
1 context sentence(design, population, supporting numbers)
Summary · context
Two subjects with the type A phenotype of severe insulin resistance without insulin receptor mutations were investigated to assess insulin secretion, insulin action, and carbohydrate tolerance before and after 3-4 weeks of rhIGF-I treatment (100 micrograms/kg, sc, twice daily).
Report a problemFND-0802722810
11HumanCase report or seriesEfficacy outcome
In subject 2 with type A severe insulin resistance, mean daily serum insulin fell during rhIGF-I treatment.
In plain wordsIn subject 2 with severe insulin resistance, mean daily serum insulin fell during rhIGF-I treatment.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseSubject 2 mean 24-h insulin
Study
n = 1
Outcome group
Glycemic control · Metabolic and weight
Studied dose
100 micrograms/kg twice daily · subcutaneous · 3-4 weeksAs given in this study (human).
Measurements
24-h mean serum insulin
892 pmol/L
subject 2, before rhIGF-I
24-h mean serum insulin
521 pmol/L
subject 2, during rhIGF-I
Reported +/- term for 24-h mean serum insulin
635 pmol/L
subject 2, before rhIGF-I; uncertainty type not stated
Reported +/- term for 24-h mean serum insulin
293 pmol/L
subject 2, during rhIGF-I; uncertainty type not stated
Source sentences
Summary
Twenty-four-hour mean serum insulin fell from 892 +/- 635 to 521 +/- 293 pmol/L, and first phase insulin secretion was restored during the iv glucose tolerance test.
2 context sentences(design, population, supporting numbers)
Summary · context
In subject 2, fasting blood glucose fell from 12.0 to 7.4 mmol/L and 24-h mean blood glucose fell from 12.7 +/- 1.9 to 6.6 +/- 1.3 mmol/L.
Summary · context
Two subjects with the type A phenotype of severe insulin resistance without insulin receptor mutations were investigated to assess insulin secretion, insulin action, and carbohydrate tolerance before and after 3-4 weeks of rhIGF-I treatment (100 micrograms/kg, sc, twice daily).
Report a problemFND-0802722811
12HumanCase report or seriesEfficacy outcome
In subject 2 with type A severe insulin resistance, first phase insulin secretion was restored during rhIGF-I treatment.
In plain wordsIn subject 2 with severe insulin resistance, first phase insulin secretion was restored during rhIGF-I treatment.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseSubject 2 first phase insulin secretion
Study
n = 1
Outcome group
Glycemic control · Metabolic and weight
Studied dose
100 micrograms/kg twice daily · subcutaneous · 3-4 weeksAs given in this study (human).
Source sentences
Summary
Twenty-four-hour mean serum insulin fell from 892 +/- 635 to 521 +/- 293 pmol/L, and first phase insulin secretion was restored during the iv glucose tolerance test.
2 context sentences(design, population, supporting numbers)
Summary · context
In subject 2, fasting blood glucose fell from 12.0 to 7.4 mmol/L and 24-h mean blood glucose fell from 12.7 +/- 1.9 to 6.6 +/- 1.3 mmol/L.
Summary · context
Two subjects with the type A phenotype of severe insulin resistance without insulin receptor mutations were investigated to assess insulin secretion, insulin action, and carbohydrate tolerance before and after 3-4 weeks of rhIGF-I treatment (100 micrograms/kg, sc, twice daily).
Report a problemFND-0802722812

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.